MXPA03004947A - Derivados de tetralona como agentes antitumorales. - Google Patents

Derivados de tetralona como agentes antitumorales.

Info

Publication number
MXPA03004947A
MXPA03004947A MXPA03004947A MXPA03004947A MXPA03004947A MX PA03004947 A MXPA03004947 A MX PA03004947A MX PA03004947 A MXPA03004947 A MX PA03004947A MX PA03004947 A MXPA03004947 A MX PA03004947A MX PA03004947 A MXPA03004947 A MX PA03004947A
Authority
MX
Mexico
Prior art keywords
antitumor agents
tetralone derivatives
tetralone
derivatives
antitumor
Prior art date
Application number
MXPA03004947A
Other languages
English (en)
Inventor
Tibes Ulrich
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA03004947A publication Critical patent/MXPA03004947A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C07D295/116Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MXPA03004947A 2000-12-07 2001-12-06 Derivados de tetralona como agentes antitumorales. MXPA03004947A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126820 2000-12-07
PCT/EP2001/014311 WO2002046144A1 (en) 2000-12-07 2001-12-06 Tetralone derivatives as antitumor agents

Publications (1)

Publication Number Publication Date
MXPA03004947A true MXPA03004947A (es) 2003-09-10

Family

ID=8170594

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03004947A MXPA03004947A (es) 2000-12-07 2001-12-06 Derivados de tetralona como agentes antitumorales.

Country Status (26)

Country Link
US (1) US6531472B2 (es)
EP (1) EP1349830A1 (es)
JP (1) JP4091431B2 (es)
KR (1) KR20030077551A (es)
CN (1) CN100340545C (es)
AR (1) AR035659A1 (es)
AU (2) AU1607402A (es)
BG (1) BG107889A (es)
BR (1) BR0115988A (es)
CA (1) CA2430355A1 (es)
CZ (1) CZ20031833A3 (es)
EC (1) ECSP034642A (es)
HK (1) HK1060875A1 (es)
HR (1) HRP20030451A2 (es)
HU (1) HUP0400579A2 (es)
IL (1) IL156133A0 (es)
MA (1) MA26972A1 (es)
MX (1) MXPA03004947A (es)
NO (1) NO20032531L (es)
NZ (1) NZ526051A (es)
PL (1) PL365324A1 (es)
RU (1) RU2288220C2 (es)
SK (1) SK8512003A3 (es)
WO (1) WO2002046144A1 (es)
YU (1) YU45803A (es)
ZA (1) ZA200304262B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US20040087657A1 (en) * 2001-10-16 2004-05-06 Richon Victoria M. Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
NZ567758A (en) 2002-03-04 2009-07-31 Merck Hdac Res Llc Methods of inducing terminal differentiation using suberoylanilide hydrozmic acid (SAHA)
WO2003083067A2 (en) * 2002-03-28 2003-10-09 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
EP1492596A1 (en) * 2002-04-05 2005-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1570061A2 (en) * 2002-12-05 2005-09-07 Imperial College Innovations Limited Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide
US7375228B2 (en) * 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
ATE462426T1 (de) 2003-08-26 2010-04-15 Merck Hdac Res Llc Verwendung von saha zur behandlung von mesotheliom
US20070190022A1 (en) 2003-08-29 2007-08-16 Bacopoulos Nicholas G Combination methods of treating cancer
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
CA2561954A1 (en) * 2004-04-05 2005-10-20 Myogen, Inc. Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
WO2005099747A1 (en) * 2004-04-14 2005-10-27 Medical Research Council Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6
KR100632800B1 (ko) 2004-10-21 2006-10-16 한국화학연구원 히스톤 디아세틸라제 저해활성을 갖는 신규한하이드록시아마이드 유도체 및 이의 제조 방법
WO2006066133A2 (en) * 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006122319A2 (en) * 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
TWI365068B (en) 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
ZA200800901B (en) * 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1976835A2 (en) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007145704A2 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド アンジオテンシン調節による神経新生
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP3052662B1 (en) 2013-10-01 2019-05-15 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
EP3769757A3 (en) * 2013-10-18 2021-10-06 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
TWI799691B (zh) * 2019-03-29 2023-04-21 景凱生物科技股份有限公司 具有側鏈烷基與烯基延伸的苯基衍生物及包括有其的藥學組合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023194441A1 (en) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448730A (en) * 1981-03-24 1984-05-15 Riet Bartholomeus Van T Hydroxybenzohydroxamic acids, benzamides and esters and related compounds as ribonucleotide reductase inhibitors
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5637946A (en) * 1993-10-28 1997-06-10 Lockheed Corporation Thermally energized electrical power source
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds

Also Published As

Publication number Publication date
NZ526051A (en) 2004-12-24
CA2430355A1 (en) 2002-06-13
ECSP034642A (es) 2003-07-25
US20020065282A1 (en) 2002-05-30
HUP0400579A2 (hu) 2004-06-28
PL365324A1 (en) 2004-12-27
ZA200304262B (en) 2004-08-30
NO20032531D0 (no) 2003-06-04
HK1060875A1 (en) 2004-08-27
BG107889A (bg) 2004-06-30
KR20030077551A (ko) 2003-10-01
JP2004515488A (ja) 2004-05-27
RU2288220C2 (ru) 2006-11-27
AR035659A1 (es) 2004-06-23
MA26972A1 (fr) 2004-12-20
NO20032531L (no) 2003-06-04
CZ20031833A3 (cs) 2004-02-18
CN100340545C (zh) 2007-10-03
CN1478072A (zh) 2004-02-25
BR0115988A (pt) 2004-01-13
US6531472B2 (en) 2003-03-11
WO2002046144A1 (en) 2002-06-13
YU45803A (sh) 2006-05-25
HRP20030451A2 (en) 2005-04-30
AU2002216074C1 (en) 2006-12-07
IL156133A0 (en) 2003-12-23
SK8512003A3 (en) 2004-04-06
AU2002216074B2 (en) 2006-01-05
EP1349830A1 (en) 2003-10-08
AU1607402A (en) 2002-06-18
JP4091431B2 (ja) 2008-05-28

Similar Documents

Publication Publication Date Title
MXPA03004947A (es) Derivados de tetralona como agentes antitumorales.
ZA200300793B (en) Substituted-triazolopyrimidines as anticancer agents.
MXPA03002410A (es) 4-amino-quinazolinas.
ZA200108530B (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents.
MXPA03003800A (es) 1-aril-o 1-alquilsulfonil-heterociclilbenzazoles como ligandos de 5-hidroxitriptamina-6.
MXPA03004593A (es) Derivados de naftaleno.
MXPA03005445A (es) Barra colectora 12c para aislar los circuitos integrados seleccionados para una comunicacion rapida de barra colectora 12c.
AU2002224595A1 (en) Antitumor agents
MXPA03004644A (es) Derivados de fenilacetamdia-pirazol y su uso como agentes antitumorales.
MXPA03002452A (es) Derivados de resorcinol.
HK1069171A1 (en) Substituted 6H-dibenzioÄc,hÜchromenes as estrogenic agents.
EG23262A (en) Delta -pyrrolines.
HK1055426A1 (en) Indoloquinazolinones.
MXPA03000107A (es) Pirroloquinolonas como agentes antivirales.
MXPA03008140A (es) Amidas de acido benzofuran-2-carboxilico sustituidas.
AU6807501A (en) 1-aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
MXPA03001591A (es) Derivados y analogos de 10-aril-11-h-benzo(b) fluorena para uso medicinal.
MXPA03001877A (es) 2-guanidin-4-arilquinazolinas.
MXPA03002668A (es) Guanidinas de sulfonilo.
MXPA03005714A (es) Sulfamidotienopirimidinas.
HK1050889A1 (en) Substituted aminomehyl-phenyl-cyclohexane derivatives.
HK1052925A1 (en) Substituted 1-aminobutan-3-ol derivatives.
MXPA03002411A (es) 4-amino-quinazolinas.
ZA200205482B (en) Aminosulfonylbiphenyl derivatives.
HK1050890A1 (en) Aminomethyl -phenyl-cyclohexanone derivatives.

Legal Events

Date Code Title Description
FG Grant or registration